NYSE · Healthcare
Solventum Corp (SOLV)
As-reported financials and recent SEC filings for Solventum Corp, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$8.32B
Net income
$1.56B
Net margin
18.7%
Diluted EPS
$8.88
ROE
30.8%
P/E (TTM)
9.7×
Market cap
$13.77B
Debt / equity
1.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2024 | FY2024 |
|---|---|---|---|---|
| Revenue | $8.32B | $8.25B | $8.20B | $8.13B |
| Gross profit | — | — | — | — |
| Operating income | $2.18B | $1.04B | $1.69B | $1.69B |
| Net income | $1.56B | $479.0M | $1.35B | $1.34B |
| Diluted EPS | $8.88 | $2.76 | $7.79 | $7.78 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-05
View on EDGAR →SD2026-05-29
View on EDGAR →8-K2026-05-27
View on EDGAR →8-K2026-05-20
View on EDGAR →42026-05-18
View on EDGAR →42026-05-18
View on EDGAR →42026-05-18
View on EDGAR →42026-05-18
View on EDGAR →Go deeper on SOLV
Search Solventum Corp’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.